Archives of Toxicology

, Volume 47, Issue 3, pp 179–189

Neurotoxicity of acrylamide and related compounds and their effects on male gonads in mice

  • Kazuo Hashimoto
  • Junko Sakamoto
  • Hideji Tanii
Original Investigations

Abstract

Neurotoxicity of acrylamide and related compounds and their effects on the testis after repeated oral doses were studied in mice. Of fourteen analogues tested, five produced neuropathy. In decreasing order of potency as assessed by the rotarod performance test, these were as follows: acrylamide > N-isopropylacrylamide > N-methylacrylamide = methacrylamide > N-hydroxymethylacrylamide. The development of neurotoxicity was either greatly reduced or delayed by phenobarbital treatment. Acrylamide, N-hydroxymethylacrylamide, N-isopropylacrylamide, N-methylacrylamide and N,N′-methylene-bis-acrylamide produced testicular atrophy. Atrophy was either prevented by phenobarbital treatment, as in the cases of acrylamide and N-isopropylacrylamide, or reduced, as in the case of N-hydroxymethylacrylamide. Histological changes in the testis produced by the active compounds were degenerations of the epithelial cells of the seminiferous tubules, with the interstitial cells being normal.

Key words

Acrylamide analogues Acrylamide N-tert-Butylacrylamide Crotonamide Diacetone acrylamide N,N-Diethylacrylamide N,N-Dimethylacrylamide N-Hydroxymethylacrylamide Iodoacetamide N-Isobutoxymethylacrylamide N-Isopropylacrylamide Methacrylamide N-Methylacrylamide N,N′-Methylene-bis-acrylamide N-tert-Octylacrylamide Neuropathy Testicular damage Phenobarbital Mice 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Drees DT, Crago FL, Hopper CR, Smith JM (1976) Subchronic percutaneous toxicity of acrylamide and methacrylamide in the new-born rabbit. Toxicol Appl Pharmacol 37: 190Google Scholar
  2. Dunham NW, Miya TS (1957) A note on a simple apparatus for detecting neurological deficit in rats and mice. J Am Pharm Assoc 46: 208–209Google Scholar
  3. Edwards PM (1975a) Neurotoxicity of acrylamide and its analogues and effects of these analogues and other agents on acrylamide neuropathy. Br J Ind Med 32: 31–38Google Scholar
  4. Edwards PM (1975b) The distribution and metabolism of acrylamide and its neurotoxic analogues in rats. Biochem Pharmacol 24: 1277–1282Google Scholar
  5. Hashimoto K, Aldridge WN (1970) Biochemical studies on acrylamide. A neurotoxic agent. Biochem Pharmacol 19: 2591–2604Google Scholar
  6. Hashimoto K, Sakamoto J, Tanii H (1979) Gonadotropic effects of acrylamide and N-hydroxymethylacrylamide in animals. Proc Medichem Conf: 278–289Google Scholar
  7. Kaplan ML, Murphy SL, Gilles FH (1973) Modification of acrylamide neuropathy in rats by selected factors. Toxicol Appl Pharmacol 24: 564–579Google Scholar
  8. Langvardt PW, Putzig JD, Young JD, Braun WH (1979) Isolation and identification of urinary metabolites of vinyl-type compounds. Toxicol Appl Pharmacol 48: A54Google Scholar
  9. McCollister DD, Oyen F, Rowe VK (1964) Toxicology of acrylamide. Toxicol Appl Pharmacol 6: 172–181Google Scholar
  10. Sharma RP, Obersteiner EJ (1977) Acrylamide cytotoxicity in chick ganglia cultures. Toxicol Appl Pharmacol 42: 149–156Google Scholar
  11. Smythe CV (1936) The reaction of iodoacetate and of iodoacetamide with various sulphydryl groups, with ureas, and with yeast preparations. J Biol Chem 114: 601–612Google Scholar
  12. Spencer PS, Schaumburg HH (1974a) A review of acrylamide neurotoxicity, Part I. Properties, uses and human exposure. Can J Neurol Sci 1: 143–150Google Scholar
  13. Spencer PS, Schaumburg HH (1974b) A review of acrylamide neurotoxicity. Part II. Experimental animal neurotoxicity and pathologic mechanisms. Can J Neurol Sci 1: 152–169Google Scholar
  14. SRI (1976) Stanford Research Institute: Directory of chemical producers (1975); cited from Investigation of selected potential environmental contaminants: Acrylamide. US Department of CommerceGoogle Scholar
  15. Weil CS (1952) Tables for convenient calculation of median effective dose (LD50 or ED50) and instructions in their use. Biometrics 8: 249–263Google Scholar

Copyright information

© Springer-Verlag 1981

Authors and Affiliations

  • Kazuo Hashimoto
    • 1
  • Junko Sakamoto
    • 1
  • Hideji Tanii
    • 1
  1. 1.Department of HygieneSchool of Medicine, Kanazawa UniversityKanazawaJapan

Personalised recommendations